Drugs in Treating Urinary Schistosomiasis

Urinary schistosomiasis caused by trematodes of the genus Schistosoma known as Schistosoma haematobium. Schistosoma haematobium, also known to be “urinary blood fluke” that inhabits and multiplies eggs in the small venules of the perivesical and portal systems. Urinary schistosomiasis is endemic in 53 countries in Africa and the Middle East. A cholinesterase inhibitor Metrifonate is another selective treatment for SH; it has good efficacy and safety properties. Although it is economic, causes low recurrence rates. Metrifonate is that a prophylactic dose which is needed within two years to guard against recurrence. Niridazole is also highly effective for treating schistosomiasis, and a single dose of niridazole daily has a high cure rate.

  • In vitro studies
  • Albendazole Treatment
  • Egg Reduction Rate

Related Conference of Drugs in Treating Urinary Schistosomiasis

November 08-09, 2021

International Conference on Immunology Research

Las Vegas, USA
December 17-18, 2021

11th International Conference on Bacteriology and Infectious Diseases

Cape Town, South Africa
December 20-21, 2021

9th World Summit on Immunology & Immunotherapy

Prague, Czech Republic
December 23-23, 2021

13th Annual Conference on Clinical Immunology

Cape Town, South Africa
December 23-23, 2021

3rd International Conference on Viral Infection and Immune Response

Amsterdam, Netherlands
February 07-08, 2022

International Conference on Vaccine Research

Paris, France
March 21-22, 2022

37th International Conference on Immunology

Brussels, Aland Islands
March 21-22, 2022

15th Global Summit on Immunology and Cell Biology

Tokyo, Japan
May 02-03, 2022

16th International Conference on European Immunology

Zurich, Switzerland

Drugs in Treating Urinary Schistosomiasis Conference Speakers

Recommended Sessions

Related Journals

Are you interested in